Dicot Pharma AB Logo

Dicot Pharma AB

Developing next-gen potency drugs for erectile dysfunction and premature ejaculation.

DICOTBT | SPGR

Overview

Corporate Details

ISIN(s):
SE0011178458 (+1 more)
LEI:
549300GX132RSE4OV407
Country:
Sweden
Address:
St Olofsgatan 11A, 753 21 Uppsala
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Dicot Pharma AB is a pharmaceutical company focused on developing the next generation of potency drugs. Its lead drug candidate, LIB-01, is in development for the treatment of erectile dysfunction and premature ejaculation. The company's objective is for LIB-01 to offer significant advantages over existing therapies, including a longer duration of effect, fewer side effects, and efficacy for a broader patient population. Dicot Pharma aims to establish LIB-01 as a first-choice treatment globally, addressing the needs of the over 500 million men worldwide affected by these conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dicot Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dicot Pharma AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dicot Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-12 Tullbacken Aktiebolag Other Buy 35,000 40,250.00 SEK
2024-09-10 Amandus Jabin Other Sell 110,000 4,276,800.00 SEK
2024-09-03 Jörgen Larsson Other Other 315,000 N/A
2024-09-02 Patrick Lawlor Other Buy 77,500 1,158,625.00 SEK
2024-09-02 Oskar Hellström Other Buy 75,000 1,121,250.00 SEK
2024-09-02 Martin Walfisz Other Other 2,108,718 442,830.78 SEK
2024-08-31 Bonny Heeren Other Other 5,000,000 550,000.00 SEK
2024-08-30 Per-Anders Hedin Other Other 5,000,000 110,000.00 SEK
2024-08-30 Erik Markus Näsholm Other Other 2,000,000 42,600.00 SEK
2024-08-30 Greger Larsson Other Other 1,600,000 34,080.00 SEK

Peer Companies

Sweden
MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland
MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland
MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany
MOR
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel
NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden
ONCOZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.